Patients with stage IA HER2+ breast cancer and smaller tumors had high BCSS rates whether they received adjuvant chemotherapy or not.

Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, ...

In the first randomized trial of its kind, researchers found that adding chemoradiation to adjuvant chemotherapy did not ...

Patients who had positive ctDNA tests after surgery were almost twice as likely to be alive at 3 years if they received adjuvant celecoxib in addition to chemotherapy, whereas the ...

Discover a study that revealed that patients receiving induction chemotherapy before radical nephroureterectomy experienced ...

Discover how AI and machine learning predict breast cancer recurrence locations and metastasis, improving risk assessment and patient care.

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...